The  South African Health Products Regulatory Authority (SAHPRA) said on Thursday that it had authorised the use of Merck’s COVID-19 treatment pill Molnupiravir. SAHPRA added in a statement that Pfizer had submitted an application for its COVID-19 pill, Paxlovid, which was under consideration. “The authorisation of Molnupiravir for compassionate use offers further therapy in the fight against COVID-19,” SAHPRA’s Chief Executive Boitumelo Semete-Makokotlela said. SAHPRA said Molnupiravir was only indicated for use in patients aged 18 years and older. It authorised with conditions the importation of a limited quantity of molnupiravir capsules for a period of six months.  Read full media release: https://t.co/dvD5o5HSag#SAHPRA #molnupiravir #COVID19 — SAHPRA (@SAHPRA1) February 17, 2022 